NCT02289209 2025-03-06
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
University of Pittsburgh
Phase 2 Completed
University of Pittsburgh
University of Calgary
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center